A Randomized, Single-blinded, Parallel Design Phase I Clinical Trial to Investigate the Safety and Pharmacokinetics/Pharmacodynamics of CKD-841 A-1, CKD-841 D or Leuplin Inj. After Subcutaneous Injection in Postmenopausal Female
Latest Information Update: 05 Apr 2023
At a glance
- Drugs Leuprorelin (Primary)
- Indications Cancer
- Focus Pharmacokinetics
- Sponsors Chong Kun Dang
- 14 Apr 2021 New trial record